Status:
TERMINATED
Twice Against Thrice-weekly Hemodialysis
Lead Sponsor:
Saint-Joseph University
Conditions:
Hemodialysis Complication
Eligibility:
All Genders
18-95 years
Phase:
NA
Brief Summary
Hemodialysis is the most worldwide prescribed renal replacement therapy for patients with end-stage renal disease. The frequency of sessions per week remains a debatable issue. In the majority of deve...
Detailed Description
Hemodialysis (HD) is the most worldwide prescribed renal replacement therapy for patients with end-stage renal disease. This treatment that relies heavily on technology has undergone major modificatio...
Eligibility Criteria
Inclusion
- all incident patients 18 years and older with CKD stage 5 started on hemodialysis.
Exclusion
- late-stage cancer patients and participants who are terminally ill defined as having an expected survival of less than 3 months.
Key Trial Info
Start Date :
February 16 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 25 2022
Estimated Enrollment :
208 Patients enrolled
Trial Details
Trial ID
NCT03415776
Start Date
February 16 2018
End Date
October 25 2022
Last Update
October 28 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Saint-Georges Hospital
Ajaltoun, Keserwan, Lebanon